Sign inJoin waitlistJoin the waitlist

Andrea Hendrickson

Associate Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2019–2022
Mayo Clinic College of Medicine and Science
2017–2019
Radiology-Diagnostic
Mayo Clinic College of Medicine and Science
2013–2017
Internal Medicine
Mayo Clinic College of Medicine and Science
2005–2008
Univ of Minnesota, Duluth Sch of Med
2001–2005

Research

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology · 2019 · 431 citations
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
JAMA Oncology · 2019 · 378 citations
Human monocytes express CD163, which is upregulated by IL-10 and identical to p155
Cytokine · 2000 · 248 citations

Scott Kaufmann
21 papers
John Weroha
17 papers
Elizabeth Swisher
12 papers
Matthew Block
10 papers
AJ
Aminah Jatoi
9 papers
Gottfried Konecny
8 papers
AO
Alexander Olawaiye
7 papers
Amanika Kumar
7 papers
PH
Paul Haluska
7 papers
Carrie Langstraat
6 papers
Gretchen Glaser
6 papers · 1 as a fellow
Ursula Matulonis
6 papers

Clinical trials

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Principal investigator · Active not recruiting · Phase 2
Mayo Clinic
2022–2030
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2017–2027
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2012–2019
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2009–2027